Markets:

Overview

News

Currencies

International

Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

42.94 -0.04 (-0.09%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

21 22 Next >

Bristol Myers Squibb-Exelixis Highlight Three-Year Follow Up Data From Opdivo+Cabometyx Combo Therapy In Kidney Cancer ↗

February 14, 2023

Via Benzinga

2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

February 14, 2023

These stocks may soon start turning heads with their revenue growth.

Via The Motley Fool

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

February 13, 2023

From Bristol Myers Squibb and Exelixis, Inc.

Via Business Wire

Looking Into Exelixis's Return On Capital Employed ↗

February 08, 2023

Via Benzinga

Exelixis (EXEL) Q4 2022 Earnings Call Transcript ↗

February 08, 2023

EXEL earnings call for the period ending December 31, 2022.

Via The Motley Fool

Earnings Outlook For Exelixis ↗

February 06, 2023

Via Benzinga

6 Analysts Have This to Say About Exelixis ↗

January 11, 2023

Via Benzinga

Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

February 13, 2023

From Exelixis, Inc.

Via Business Wire

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

February 12, 2023

These companies could grow in prominence in the coming years.

Via The Motley Fool

Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

February 07, 2023

From Exelixis, Inc.

Via Business Wire

3 No-Brainer Stocks to Buy Right Now for Less Than $25 ↗

February 04, 2023

All three healthcare stocks are showing solid long-term potential.

Via The Motley Fool

Is Exelixis Stock a Buy Now? ↗

December 29, 2022

Don't be too quick to dismiss this company as a one-trick pony.

Via The Motley Fool

What 5 Analyst Ratings Have To Say About Exelixis ↗

December 09, 2022

Via Benzinga

Where Exelixis Stands With Analysts ↗

December 09, 2022

Via Benzinga

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February

February 02, 2023

From Exelixis, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023 ↗

January 26, 2023

Via Benzinga

Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023

January 24, 2023

From Exelixis, Inc.

Via Business Wire

Exelixis' Patent Decision In Line With Expectations, But Analysts Say Stock Overhang Could Continue ↗

January 20, 2023

Via Benzinga

Exelixis Announces Update on Patent Litigation with MSN Laboratories

January 19, 2023

From Exelixis, Inc.

Via Business Wire

7 Biotech Stocks That Will Make You Rich in 10 Years ↗

January 18, 2023

Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.

Via InvestorPlace

Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023

January 08, 2023

From Exelixis, Inc.

Via Business Wire

Four Undervalued Healthcare Stocks for 2023

January 06, 2023

These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.

Via MarketBeat

Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —

January 03, 2023

From Exelixis, Inc.

Via Business Wire

2 Top Biotech Stocks to Buy for the Long Haul ↗

December 25, 2022

These mid-cap biotechs are solid long-term choices.

Via The Motley Fool

Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer

December 22, 2022

From Exelixis, Inc.

Via Business Wire

2 Beaten-Down Growth Stocks to Buy Before the Bull Run ↗

December 21, 2022

These could become hot buys once investors pivot back to growth stocks.

Via The Motley Fool

2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague ↗

December 16, 2022

Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint.

Via The Motley Fool

Nasdaq Bear Market: 5 Exceptionally Cheap Growth Stocks You'll Regret Not Buying on the Dip ↗

December 10, 2022

These bargain-basement-priced growth stocks are ripe for the picking following a 38% peak decline in the Nasdaq Composite.

Via The Motley Fool

Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting ↗

December 09, 2022

Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study

Via Benzinga

Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy

December 08, 2022

From Exelixis, Inc.

Via Business Wire

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Exelixis, Inc. - Common Stock (NQ:EXEL)

All News about Exelixis, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today